Search for Clinical Trial Results

Sponsored By

Erythema Multiforme - 25 Studies Found

Status Study
Completed Study Name: Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
Condition: Plaque Psoriasis
Date: 2013-06-26
Interventions: Drug: Clobex Spray Other Name: Clobetasol propionate spray
Recruiting Study Name: A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
Condition: Stage IV Non-Small Cell Lung Cancer
Date: 2016-01-14
Interventions:
  • Drug: Pembrolizumab 200mg Pemb
Not yet recruiting Study Name: Discerning Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Guided Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Condition:
  • Prostate Cancer
  • Magnetic Resonance Imaging
  • Device: MRI/ultrasound transperineal fusion-guided prostate biopsy

Completed Study Name: Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
Condition: Head and Neck Cancer
Date: 2001-08-10
Interventions: Drug: liposomal lurtotecan
Active, not recruiting Study Name: Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis (Dialysis Fistulae)
Condition:
  • Vascular Access Complication
  • Restenosis, Vascular Graft
  • Di
    Date: 2017-01-19
    Interventions:
    • Device: Conventional angioplasty

Recruiting Study Name: Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study
Condition: Toxic Epidermal Necrolysis
Date: 2016-06-06
Interventions:
  • Drug: Isotretinoin
  • Other: Placebo
Recruiting Study Name: Severe Cutaneous Adverse Reactions in Thailand
Condition:
  • Steven-Johnson Syndrome
  • Toxic Epidermal Necrolysis
  • Drug Re
    Date: 2015-10-12
Recruiting Study Name: HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction
Condition:
  • Stevens-Johnson Syndrome
  • Kidney Failure, Chronic

Date: 2017-02-06
Interventions: Genetic: HLA-B*5801 test Check whether a participant has HLA-B*5801 allele or not, before administration
Not yet recruiting Study Name: Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Condition:
  • Stevens-Johnson Syndrome
  • Toxic Epidermal Necrolyses

Date: 2016-11-25
Interventions:
  • Drug: cyclosporin A Other Name
Active, not recruiting Study Name: Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation
Condition:
  • Graft vs Host Disease
  • Congenital Aniridia
  • Chemical Burns Date: 2016-09-07
    Interventions: Device: ARGOS-IO system This study will enroll a minimum of 10 and a maximum of 15 patients. It is antic
Next >>>